Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 25:11:100121.
doi: 10.1016/j.obpill.2024.100121. eCollection 2024 Sep.

Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs

Sandra Christensen  1 , Katie Robinson  2 , Sara Thomas  2 , Dominique R Williams  2
Affiliations
Review

Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs

Sandra Christensen et al. Obes Pillars. .

Erratum in

Abstract

Background: Obesity and type 2 diabetes mellitus (T2DM) are increasingly common in the United States and worldwide. Because both conditions are associated with serious health consequences, weight reduction is recommended by professional medical and nutrition societies to improve outcomes. Due to the striking efficacy of glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) for weight reduction and glycemic control, there is increased utilization for patients with obesity and/or T2DM. Yet, the impact of these medications on dietary intake is less understood.

Methods: This narrative literature review summarizes clinical studies quantifying and characterizing dietary intake in people with obesity and/or T2DM using GLP-1 or GIP/GLP-1 RAs.

Results: Though data from these studies reveal that total caloric intake was reduced by 16-39 %, few studies evaluated the actual composition of the diet.

Conclusions: Further research is needed to understand the unique nutritional needs of adults on GLP-1 or dual GIP/GLP-1RAs and to support the development of nutritional guidelines for these individuals.

Keywords: GIP/GLP-1 receptor agonist; GLP-1 receptor agonist; Nutrition; Obesity; Sarcopenia; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

All the authors listed have approved the manuscript and have no conflicts of interest on this paper. KR, ST, and DW are employees and stockholders of Abbott (Abbott Park, IL, USA).

Figures

Image 1
Graphical abstract
See this image and copyright information in PMC

References

    1. Khan M.A.B., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–111. - PMC - PubMed
    1. Donini L.M., Busetto L., Bischoff S.C., et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr. 2022;41(4):990–1000. - PubMed
    1. Fryar C., Carroll M., Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States 1960-1962 and 2017-2018. 2021. https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/overweight-obes...
    1. Centers for Disease Control and Prevention National diabetes statistics report website. 2023. https://www.cdc.gov/diabetes/data/statistics-report/index.html
    1. Lopez-Pedrosa J., Camprubi-Robles M., Guzman-Rolo G., et al. The vicious cycle of type 2 diabetes mellitus and skeletal muscle atrophy: clinical, biochemical, and nutritional bases. Nutrients. 2024;16:172. - PMC - PubMed

LinkOut - more resources